Please use this identifier to cite or link to this item:
Title: Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells
Authors: Yuen, Hiu-Fung
Abramczyk, Olga
Montgomery, Grant
Chan, Ka-Kui
Huang, Yu-Han
Sasazuki, Takehiko
Shirasawa, Senji
Gopesh, Srivastava
Chan, Kwok-Wah
Fennell, Dean
Janne, Pasi
Ei-Tanani, Mohamed
Murray, James T.
First Published: 6-Jun-2012
Publisher: BMJ Publishing Group Ltd
Citation: Bioscience Reports, 2012, 32, pp. 413 – 422
Abstract: Synopsis: Inhibition of the PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mammalian target of rapamycin complex 1) and Ras/MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK pathways for cancer therapy has been pursued for over a decade with limited success. Emerging data have indicated that only discrete subsets of cancer patients have favourable responses to these inhibitors. This is due to genetic mutations that confer drug insensitivity and compensatory mechanisms. Therefore understanding of the feedback mechanisms that occur with respect to specific genetic mutations may aid identification of novel biomarkers that predict patient response. In the present paper, we show that feedback between the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways is cell-line-specific and highly dependent on the activating mutation of K-Ras or overexpression c-Met. We found that cell lines exhibited differential signalling and apoptotic responses to PD184352, a specific MEK inhibitor, and PI103, a second-generation class I PI3K inhibitor. We reveal that feedback from the PI3K/Akt/mTORC1 to the Ras/MEK/ERK pathway is present in cancer cells harbouring either K-Ras activating mutations or amplification of c-Met but not the wild-type counterparts. Moreover, we demonstrate that inhibition of protein phosphatase activity by OA (okadaic acid) restored PI103-mediated feedback in wild-type cells. Together, our results demonstrate a novel mechanism for feedback between the PI3K/Akt/mTORC1 and the Ras/MEK/ERK pathways that only occurs in K-Ras mutant and c-Met amplified cells but not the isogenic wild-type cells through a mechanism that may involve inhibition of a specific endogenous phosphatase(s) activity. We conclude that monitoring K-Ras and c-Met status are important biomarkers for determining the efficacy of PI103 and other PI3K/Akt inhibitors in cancer therapy.
DOI Link: 10.1042/BSR20120050
ISSN: 0144-8463
eISSN: 1573-4935
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence ( by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
Appears in Collections:Published Articles, MRC Toxicology Unit

Files in This Item:
File Description SizeFormat 
10.1042_BSR20120050.pdfPublished (publisher PDF)1.16 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.